
... BIBLIOGRAPHY ...

- Ambrose PG, Quintiliani R, Nightingale CH, Nicolau DP. Continuous vs. intermittent infusion of cefuroxime for the therapy of community-acquired pneumonia. *Infect Dis Clin Pract*, In press.
- American Society for Microbiology. Report of the ASM task force on antibiotic resistance. *Antimicrob Agents Chemother* 1995;Suppl:1-23.
- American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. *Am Rev Respir Dis* 1993;148:1418-1426.
- Amsden GW. Erythromycin, clarithromycin and azithromycin: Are their differences real? *Clin Ther* 1996;18:56-72.
- Anthonisen NR, Manfred J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;106:196-204.
- Applebaum. Antimicrobial resistance in *Streptococcus pneumoniae*: An overview. *Clin Inf Dis J* 1992;15:77-83.
- Arai S, Gohara Y, Gohara Y, Kuwano K, Kawashima T. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against *Mycoplasma pneumoniae*. *Antimicrob Agents Chemother* 1992;36:1322-1324.
- Balfour JA, Wagstaff AJ. Treatment of community acquired pneumonia and acute exacerbation of COPD with grepafloxacin. *Drugs* 1997;53:614.
- Barry AL, Fuchs PC, Brown SD. In vitro activities of five fluoroquinolone compounds against strains of *Streptococcus pneumoniae* with resistance to other antimicrobial agents. *Antimicrob Agents Chemother* 1996;40:2431-2433.
- Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. *Antimicrob Agents Chemother* 1994;38:2419-2425.
- Bartlett JG. Community-acquired pneumonia today: Pathogen-directed therapy and resistance patterns. *Hosp Med* 1997;33(suppl):10-13.
- Bartlett JG, et al. Community acquired pneumonia in adults: Guidelines for management. *J Clinical Infectious Diseases* 1998;26:811-838.
- Bartlett JG, Mundy LM. Community-acquired pneumonia. *N Engl J Med* 1995;331:618-624.
- Bartlett JG. IDCP guidelines: Lower respiratory tract infections. *Infect Dis Clin Pract* 1996;5:147-167.
- Beringer PM, Holtom MD, Rho JP. Comparing the newest fluoroquinolones: Levofloxacin and sparfloxacin. *Formulary* 1997;32:926-943.
- Block S, Henrick J, Wright P, et al. Drug resistant *Streptococcus pneumoniae*: Kentucky and Tennessee, 1993. *MMWR* 1994;43:23-25.
- Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. *Am J Med* 1979;67:608-611.
- Boken DJ, Chartrand SA, Smith Molland E, Goering RV. Colonization with penicillin-nonsusceptible *Streptococcus pneumoniae* in urban and rural childcare centers. *Pediatr Infect Dis J* 1996;15:667-672.
- Bonatti H, Guggenbichler JP, Hager J. Treatment of nosocomial infections in children undergoing antimicrobial chemotherapy. *Infection* 1990;18:302-306.
- Bongaerts CPA, Hoogkamp-Korstanje JAA. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infectious. *Antimicrob Agents Chemother* 1993;37:2017-2019.
- Butler JC, Hofman J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant *Streptococcus pneumoniae* in the United States: Update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. *J Infect Dis* 1996;174:986-993.
- Carbon C. Quinolones in the treatment of lower respiratory tract infections in adult patients. *Drugs* 1993;45(suppl 3):91-97.
- Carilli AD, Gohd RS, Gordon WA. Virologic study of chronic bronchitis. *N Engl J Med* 1964;270:123-127.
- Cassell GH, Drnec J, Waites KB, et al. Efficacy of clarithromycin against mycoplasma pneumonia. *J Antimicrob Chemother* 1991;27(suppl A):47-59.
- Child J, Andrews J, Boswell F, Brenwald N, Wise R. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: A comparison with fluoroquinolone agents. *J Antimicrob Chemother* 1995;35:869-876.
- Chodosh S. Treatment of acute exacerbations of chronic bronchitis: State of the art. *Am J Med* 1991;91(suppl 6A):87S-92S.

... BIBLIOGRAPHY ...

- Consensus statement: Therapeutic recommendations for community acquired pneumonia and acute exacerbations of chronic bronchitis. *Hosp Med* 1997;33(suppl): 26-27.
- Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. *Diagn Microbiol Infect Dis* 1995;22:89-96.
- Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. *CID* 1998;26:1-12.
- Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: A review. *Pediatr Infect Dis J* 1991;S74:63-70.
- Craig WA, Ebert SC. Continuous infusion of β -lactam antibiotics. *Antimicrob Agents Chemother* 1992;36: 2577-2583.
- Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. *Pediatr Infect Dis J* 1996;15: 9805.
- Davis R, Bryson HM. Levofloxacin and sparfloxacin in the treatment of lower respiratory tract infections secondary to pneumococcal infections. *Drugs* 1994;47:677.
- DeAbate CA, Russell M, McElvaine P, Fowler CL. A multicenter, randomized study comparing levofloxacin (LVFX) and cefuroxime axetil (CEF) in the treatment of acute bacterial exacerbation of chronic bronchitis (AECB). Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1996. Washington, DC: American Society for Microbiology. Abstract 292.
- DeAbate CA, Russell M, McElvaine P, et al. Oral levofloxacin efficacy compared to cefuroxime axetil in patients with acute exacerbation of chronic bronchitis. *Respir Care* 1997;42:206.
- DeAbate CA, (for the SPAR Multicenter AECB Study Group). Treatment of acute bacterial exacerbations of chronic bronchitis (AECB) with Sparfloxacin (SPAR) and Ofloxacin (OFL). In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans: American Society of Microbiology, 1996. Abstract LM9.
- Doern GV. In vitro activity of loracarbef and effects of susceptibility test methods. *Am J Med* 1992;92(suppl 6A): 7S-15S.
- Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. *Am J Med* 1995; 99(suppl 6B):3S-7S.
- Doern GV, Bruegermann A, Holley HP, et al. Failure of oral advanced generation cephalosporins, erythromycin, azithromycin and clarithromycin against highly resistant pneumococci. *Antimicrob Agents Chemother* 1996;40: 1208.
- Doern GV, Brueggemann A, Holley HP J, Rauch AM. Antimicrobial resistance of *Streptococcus pneumoniae* recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. *Antimicrob Agents Chemother* 1996;40:1208-1213.
- Donowitz G, for the SPAR Multicenter CAP Study Group. Treatment of community-acquired pneumonia (CAP) with sparfloxacin (SPAR) and erythromycin (ERY). Abstracts of the 36th Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1996. Washington, DC: American Society for Microbiology. Abstract LM12.
- Eadie MB, Stott EJ, Grist NR. Virological studies in chronic bronchitis. *BMJ* 1966;2:671-673.
- Eddie LM, Vassal MA, Jacobs MR, Appelbaum PC. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. *Antimicrob Agents Chemother* 1996;40:1950-1952.
- Eliopoulos GM, Eliopoulos CT. Activity in vitro of the quinolones. In: Hooper DC, Wolfson JS, eds. *Quinolone Antimicrobial Agents*, 2nd ed. Washington, DC: American Society of Microbiology;1993:161-193.
- Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. *Antimicrob Agents Chemother* 1993;37:366-370.
- Eliopoulos GM, Wennersten CB, Moellering RC Jr. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. *Diagn Microbiol Infect Dis* 1996;25:35-41.
- Fang GD, Fine M, Yu VL, et al. New and emerging etiologies for community acquired pneumonia with implications for therapy. *Medicine* 1990;69:307-316.
- Ferber D. Presented at Association of the Prudent Use of Antibiotics; November 1997; Boston.
- Ferraro MJ. Emerging pathogens and resistance patterns in lower respiratory tract infections: Focus on community-acquired pneumonia. *Hosp Med* 1997;33(suppl):5-9.
- File TM Jr. New therapeutic options for community-acquired pneumonia and acute exacerbations of chronic bronchitis. *Hosp Med* 1997;33(suppl):18-23.

... BIBLIOGRAPHY ...

- Fish JE. Bacterial infection in acute exacerbations of chronic bronchitis: How to detect—how to manage. *Consultant* 1993;33(suppl):10-16.
- Frils B, Andersen P, Brenøe, et al. Antibiotic treatment of pneumonia and bronchiolitis: A prospective randomised study. *Arch Dis Child* 1984;59:1038-1045.
- Fuchs PC, Barry AL, Brown SD and the AST Surveillance Group. Prevalence of resistance to three fluoroquinolones: Assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. *Antimicrob Agents Chemother* 1996;40:1633-1639.
- Gargallo-Viola D, Esteve M, Llovera S, Roca X, Guinae J. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidiny tricyclic fluoroquinolone. *Antimicrob Agents Chemother* 1991;35:442-447.
- Giamarellou H. Failure of ciprofloxacin and ofloxacin in the treatment of community acquired pneumonia caused by *S. pneumoniae*. *Drugs* 1995;49(suppl 2):58.
- Gonzales R, et al. Antimicrobial prescribing for adults with colds, upper respiratory tract infections and bronchitis by ambulatory care physicians. *JAMA* 1997;278:901-904.
- Gotfried M, Nightingale CH, Ramirez J. Emerging issues in the antimicrobial treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. *Formulary* 1998;33(suppl 2):S36-S49.
- Gotfried MH. Macrolide use in the treatment of lower respiratory tract infections. *Clin Pulmonary Med* 1995;2:10-18.
- Grepafloxacin: A new fluoroquinolone. *The Medical Letter* 1998;40(1019):17-18.
- Guggenbichler JP. Influence of Macrolides on Oral Flora. Presented at the First World Congress of Pediatric Infectious Disease, Acapulco, Mexico, December 1996.
- Guggenbichler JP, Titz B, Uzun A. Beeinflussung der körpereigenen flora durch verschiedene oral verabreichte antibiotika und chemotherapeutika. *Antibiotika Monitor, Floia chemotherapeutica austriaca* 1995;11:38-43.
- Gump DW, Phillips CA, Forsyth BR, McIntosh K, Lamborn KR, Stouch WH. Role of infection in chronic bronchitis. *Am Rev Respir Dis* 1976;113:465-474.
- Habib MP, Gentry LO, Rodriguez-Gomez G, Morowitz W, Williams R. A multicenter, randomized study comparing the efficacy and safety of oral levofloxacin vs cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1996. Washington, DC: American Society for Microbiology. Abstract LM-2.
- Hall CB, Powell KR, Schnabel KC, Gala CL, Pincus PH. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. *J Pediatr* 1998;113:266-274.
- Hammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against *Chlamydia pneumoniae*. *Antimicrob Agents Chemother* 1992;36:682-683.
- Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against chlamydia pneumonia. *Antimicrob Agents Chemother* 1992;36:1573-1574.
- Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug resistant *Streptococcus pneumoniae* in Atlanta. *N Engl J Med* 1995;333:481-486.
- Isada CM. Pro: Antibiotics for chronic bronchitis with exacerbations. *Semin Respir Infect* 1993;8:243-253.
- Jackson MA, Burry FV, Olson LC, Duthie SE. Break-through sepsis in macrolide resistant pneumococcal infection. *Pediatr Infect Dis J* 1996;15:1049-1050.
- Johnson AP, et al. In vitro activity of grepafloxacin against pneumococci. *Eur J Clin Microbiol Infect Dis* 1997;16:622.
- Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Streptococcus pneumoniae* in the United States. *Antimicrob Agents Chemother* 1990;34:2075-2080.
- Kaku M, Ishida K, Irifune K, et al. In vitro and in vivo activities of sparfloxacin against *Mycoplasma pneumoniae*. *Antimicrob Agents Chemother* 1994;38:738-741.
- Kita E, Sawaki M, Oku D, et al. Suppression of virulence factors of *Pseudomonas aeruginosa* by erythromycin. *J Antimicrob Chemother* 1991;27:273-284.
- Klein JO. *Haemophilus influenzae*: Its role in pediatric infections. *Ped Infect Dis J* 1997;16:S3-S4.
- Kobayashi H. Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides. *Am J Med* 1995;99(suppl 6A):26S-30S.
- Lacy MK, Owens RC Jr, Xu X, Nicolau DP, Quintiliani R, Nightingale CH. A comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and cefuroxime axetil against *S. pneumoniae* (Abstract No. A-43). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997.

... BIBLIOGRAPHY ...

- Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community based azithromycin treatment of trachoma on carriage and resistance of *Streptococcus pneumoniae*. *CID* 1997;24:356-362.
- Leder P, Clayton DA, Rubenstein E. *Molecular Medicine*. New York: Scientific American 1994.
- Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients. *Thorax* 1996;51:179-184.
- Macfarlane J, et al. Physician antibiotic usage patterns. *Respir Med* 1997;91:427-434.
- Mandel EM, Rockette HE, Bluestone CD, Paradise JL, Nozza RJ. Antibiotic therapy for otitis media with effusion. *JAMA* 1993;269:516-517.
- Mandell GL, Bennett JE, Dolin R. *Principles and Practice of Infectious Diseases* 4th ed. New York: Churchill Livingstone. 1995.
- Mandell L. Double blind randomized trial of trovofloxacin for the treatment of uncomplicated community acquired pneumonia. *Antimicrob Agents Chemother* 1997;37:377.
- Marrie TJ, Peeling RW, Fine MJ, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. *Am J Med* 1996;101:508-115.
- Marston BJ, Plouffe JF, Breiman RF, et al. Preliminary findings of a community-based pneumonia incidence study. In: Barabee JM, Breimann RF, DuFour AP, eds. *Legionella: Current Status and Emerging Perspectives*. Washington, DC: American Society for Microbiology; 1993:36-37.
- Marston BJ, Plouffe JF, File TM Jr., et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. *Arch Intern Med* 1997;157:1709-1718.
- Moellering RC Jr. Quinolone antimicrobial agents: Overview and conclusions. In: Hooper DC, Wolfson JS, eds. *Quinolone Antimicrobial Agents*, 2nd ed. Washington, DC: American Society for Microbiology; 1993:527-535.
- Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia: Impact of immune status. *Am J Respir Crit Care Med* 1995;152:1309-1315.
- Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1976; 113:465-474.
- National Committee on Clinical Laboratory Standards. Methods for Dilution: Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 4th ed. Approved standard. NCCLS document M7-A4. 1997.
- Nelson JD, McCracken GH. Disappearance of haemophilus disease. *Ped Infect Dis J* 1997;16(3):262.
- Nicolau DP, Quintiliani R, Nightingale CH. Antibiotic kinetics and dynamics for the clinician. In: Cunha B, ed. *Medical Clinics of North America*. Philadelphia: WB Saunders, 1995;70:477-495.
- Nightingale CH, Quintiliani R, Nicolau DP. Intelligent dosing of antimicrobials. In: Remington JS, Swartz MN, eds. *Current Clinical Topics in Infectious Diseases*. Cambridge: Blackwell Scientific, 1994;14:252-265.
- Ober NS. Respiratory infection management system. *ICMAS IV* 1998;278:911-916.
- Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. *Antimicrob Agents Chemother* 1996;40: 2375-2379.
- Plouffe JF and the Franklin County Pneumonia Study Group. Levofloxacin in vitro activity against bacteremic isolates of *Streptococcus pneumoniae*. *Diagn Microbiol Infect Dis* 1996;25:43-45.
- Plouffe JF, Breiman RF, Facklam RR. Bacteremia with *Streptococcus pneumoniae*: Franklin County, Ohio: Implications for therapy and prevention. *JAMA* 1996;275: 194-198.
- Rodnick JE, Gude JK. The use of antibiotics in acute bronchitis and acute exacerbations of chronic bronchitis. *West J Med* 1988;149:347-351.
- Rodvold KA, Gotfried MH, Danzinger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. *Antimicrob Agents Chemother* 1997;41:1399-1402.
- Saint S, Brent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: A meta-analysis. *JAMA* 1995;273:957-960.
- Schaad UB, Heynen G, and the Swiss Tonsillopharyngitis Study Group. Evaluation of the efficacy, safety, and toleration of azithromycin vs penicillin V in the treatment of acute streptococcal pharyngitis in children: Results of a multicenter, open comparative study. *Pediatr Infect Dis J* 1996;15:791-795.
- Scriver SR, Walmsley SL, Kau CL, et al. Determination of antimicrobial susceptibilities of Canadian isolates of *Haemophilus influenzae* and characterization of their β -lactamases. *Antimicrob Agents Chemother* 1994;38: 1678-1680.

... BIBLIOGRAPHY ...

- Scully BE. Therapy of respiratory tract infections with quinolone antimicrobial agents. In: Hooper DC, Wolfson JS, eds. *Quinolone Antimicrobial Agents*, 2nd ed. Washington, DC: American Society for Microbiology; 1993:339-362.
- Seppala H, Klaukka T, Vuopio-Varkila J, et al and the Finnish Study Group for Antimicrobial Resistance. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in Group A streptococci in Finland. *N Engl J Med* 1997;337:441-446.
- Shea KW, Cunha BA, Ueno Y, Abumustafa F, Qadri SMH. Doxycycline activity against *Streptococcus pneumoniae*. *Chest* 1995;108:1775-1776.
- Smith CB, Golden CA, Kanner RE, Renzetti AD Jr. Association of viral and Mycoplasma pneumonia infections with acute respiratory illness in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1980;11:225-232.
- Spangler SK, Jacobs MR, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and resistant strains of *Streptococcus pneumoniae* to RP 59500, vancomycin, erythromycin, PD131628, sparfloracin, temafloxacin, Win 57273, ofloxacin, and ciprofloxacin. *Antimicrob Agents Chemother* 1992;36:856-859.
- Still JG, Hubbard WC, Pooke JM, Sheaffer CI, Chartrand S, Jacobs R. Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibiotic therapies. *Pediatr Infect Dis J* 1993;12:S134-S141.
- Tager I, Speizer F. Role of infection in chronic bronchitis. *N Engl J Med* 1975;292:563-571.
- Tanaka M, Hoshino K, Osada Y. Antimicrobial activity of DV-7751a, a new fluoroquinolone. *Antimicrob Agents Chemother* 1993;37:2112-2118.
- Trovafloxacin. *The Medical Letter* 1998;40:1022-1023.
- Ulijasz AT, Grenader A, Weisblum B. A vancomycin-inducible lacZ reporter system in *Bacillus subtilis*: Induction by antibiotics that inhibit cell wall synthesis and by lysozyme. *J Bacteriol* 1996;178:6305-6309.
- Wang EEL, Law BJ, Boucher FD, et al. Pediatric investigators collaborative network on infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. *J Pediatr* 1996;129:390-395.
- Weisblum B. Erythromycin resistance by ribosome modification. *Antimicrob Agents Chemother* 1995;39:577-585.
- Weisblum B. Insights into erythromycin action from studies of its activity as inducer of resistance. *Antimicrob Agents Chemother* 1995;38:797-805.
- Weiss LR. Clinical study of macrolides in a select patient population. *ICMAS IV* 1998;278:901-904.
- Welsh L, Gaydos C, Quinn TC. In vitro activities of azithromycin, clarithromycin, erythromycin and tetracycline against 13 strains of *Chlamydia pneumoniae*. *Antimicrobial Agents Chemother* 1996;40:212-214.
- Zekel ML. Loracarbef (LY163892) in the treatment of acute exacerbation of chronic bronchitis: Results of U.S. and European comparative clinical trials. *Am J Med* 1992;92(suppl 6A):58S-64S.